Literature DB >> 28501093

Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer.

Manish A Shah1.   

Abstract

"This issue of Hematology/Oncology Clinics of North America provides an update to the current understanding of the physiology of gastric and esophageal cancers and the state-of-the-art management of disease. Over the past 10 years, we have witnessed dramatic changes in both our understanding of the disease and its management. We have 2 new biological agents approved to treat advanced disease, with several more prospects under development. In this article, the author looks to the future, attempting to answer the question of which advancements will play the biggest role in improving patient outcomes in this still-devastating disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Helicobacter pylori; Locally advanced disease; Molecular profiling; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28501093     DOI: 10.1016/j.hoc.2017.01.010

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  The prognostic role of angiolymphatic invasion in N0 esophageal carcinoma: a meta-analysis and systematic review.

Authors:  An Wang; Yulong Tan; Yuyan Zhang; Dong Xu; Yuchao Fang; Xiaofeng Chen; Shaohua Wang
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

2.  Marital status is associated with superior survival in patients with esophageal cancer: a Surveillance, Epidemiology, and End Results study.

Authors:  Lijun Du; John J Kim; Binrui Chen; Shuwen Zhu; Ning Dai
Journal:  Oncotarget       Date:  2017-10-07

3.  Prolactin (PRL), placenta growth factor (PIGF) and nerve growth factor receptor (NGFR) as biomarkers for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma (ESCC).

Authors:  Xiaohong Ai; Xiaoxi Zhu; Jianhong Zuo
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.